An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new clinical guideline from the U.S. Department of Veterans Affairs and the Department of Defense says doctors should strongly consider prescribing two newer weight-loss drugs, semaglutide and tirzepatide, for people with obesity. The recommendation is aimed at clinicians who treat veterans and service members, and it comes after evidence that these drugs can produce substantial weight loss compared with older treatments. Semaglutide is the active ingredient in brand-name drugs like Ozempic and Wegovy. In plain terms, it acts like a natural hormone from the gut that tells your brain you’re full and slows how quickly your stomach empties. Tirzepatide is newer and works on two related gut hormones at once, so it can have an even stronger effect on appetite and blood sugar. Both are given by injection and are not the same as over-the-counter supplements. The guideline is based on clinical trial evidence in humans showing that these drugs can lead to significant weight loss when combined with lifestyle changes like diet and exercise. In many of the large trials, people lost a noticeable percentage of their body weight—often more than older medications produced. The guideline committee looked at the size and quality of those trials and concluded the benefits outweigh the downsides for many patients with obesity or related health risks. This isn’t about small, anecdotal reports; it’s driven by multiple controlled studies, though the guideline applies to specific patient groups studied in those trials. This matters because it shifts the official stance of two large government health systems toward using these modern medicines more proactively. For people with obesity, particularly those with conditions like type 2 diabetes or cardiovascular risk, this could mean greater access to treatments that actually move the needle on weight and health markers. It also signals to other care systems and insurers that these drugs are becoming a standard option rather than an experimental afterthought. There are important caveats. These medications can cause side effects like nausea, diarrhea, or constipation, and long-term safety beyond a few years is still being studied. They require injections and medical monitoring. They’re not approved for everyone — dosing, medical history, and other medications matter — and cost or insurance coverage can be a barrier. The guideline is a recommendation, not a universal mandate; individual doctors and patients still need to weigh benefits and risks together. Bottom line: The VA and DoD now strongly recommend semaglutide and tirzepatide as effective medical treatments for obesity for appropriate patients, but people should discuss benefits, side effects, and access with their clinicians.
Source: U.S. Medicine